Tá forbairtí le déanaí ar réimse leictreach draíochta le haghaidh cóireáil siadaí inchinn.
Galar marfach is ea glioclastoma ar a dtugtar an “foirceannadh” toisc go bhfásann an meall seo go han-tapa agus go bhféadfadh sé dul i bhfeidhm ar aon duine d’aois ar bith, a bhfuil prognóis lag air.
There is currently no cure for this tumor, and treatment is difficult because glioblastomas extend the antennae into the brain instead of forming a solid mass that a doctor can target and remove. So even if the surgical resection is clean, the average time to meall recurrence is only 6.9 months, and the average survival time is only 14.6 months. During the treatment process, resistance to traditional treatment is prone to occur. What is more frightening is that this kind of Tumors have a curse that has a nearly 100% chance of recurrence.
Prelude to the Diabhal atá le teacht Tilt Do Chorp go mall
Tá Scott Rider, 61 bliain d’aois, ina chónaí i Williamsport. Tá sé ar scor agus tá sé ina chónaí lena bhean chéile agus a chol ceathrar, agus tá garmhac álainn aige.
Lá amháin, bhí sé ag níochán agus fuair sé go raibh an chuma ar a chorp leanacht go dtí go ndeachaigh sé isteach sa doirteal go han-mhall…
Ní raibh a fhios aige cad a tharla, ach sna cúpla lá amach romhainn d’éirigh rudaí níos mícheart. Thosaigh sé ag mothú an-tuirseach, fiú mura ndearna sé tada, agus an-tuirseach.
The family was a little worried whether it would be Alzheimer’s disease. He accompanied him to the hospital for a systematic examination. After the diagnosis, the whole family was shocked. Rider got one of the most deadly siadaí inchinne, glioblastoma, but The predicted life can only be calculated in months, not years.
In April 2017, with the support of his family, he underwent surgery. The doctor said that at present the lesions were cut clean, but the fatality of this brain tumor is that it will definitely recur, but sooner or later the problem, so still You need to receive radiotherapy and chemotherapy as soon as possible to kill the remaining cancer cells in the body to the greatest extent and delay the recurrence as much as possible.
Réimse leictreach “draíochta” - draíocht an atarlú a ardú
Le linn na ceimiteiripe, dúirt dochtúir cóireála Rider go bhfuil modh cóireála nua ceadaithe ag an FDA anois, teiripe allamuigh leictreach, ar a dtugtar Optune freisin, ina bhfuil ceithre eochaircheap leictreoid ceangailte le scalp bearrtha an othair. Gineann sé réimse leictreach íseal-déine, minicíochta íseal a tharchuireann an tsraith transducer go suíomh an meall glioblastoma.
Electric fields can destroy rapidly dividing cancer cells, especially gliomas, a type of tumor that divides rapidly.
Mr. Rider uses MRI to monitor brain tumors every other month. He said, “In the best case, it would shrink, but for me it didn’t grow anymore, it was very stable, which was very good.
Anois, creideann Rider go bhfuil an réimse leictreach le “cumhacht draíochta” ag ardú an mhallacht athfhillteach dó, agus is é an “tairbhí” é a shábhálann beatha.
Is cuimhin leis nuair a rinne sé glioblastoma a dhiagnóisiú den chéad uair, dúirt dochtúirí nach raibh aige ach 18 go 24 mí dá shaol. Mar sin féin, tá sé anois an 27ú mí tar éis na hoibríochta, agus níl aon airíonna atarlú ann, dúirt sé go gcaithfidh sé réimse leictreach i gcónaí ionas gur féidir leis leanúint ar aghaidh ag obair.
Nuair nach mbíonn obair de dhíth ar an Uasal Rider, déanann sé cuid de na spóirt is fearr leis, mar sciáil agus haca. Nuair a bhí sé sa bhaile, d’imir sé lena gharmhac álainn freisin. Seo draíocht na teiripe allamuigh leictreach. Ligeann sé duit na cealla ailse i do chorp a rialú faoi riocht beatha go hiomlán gnáth. Tá drochthionchar ag cealla agus ag daoine timpeall orthu.
Tá súil ag an Uasal Rider go dtabharfaidh a rath dóchas do dhaoine eile. “Níl aon bhealach agam meall marfach a ruaigeadh cosúil le meall urchóideach inchinne, ach is féidir liom maireachtáil ar bhealach dearfach."
Teicneolaíocht cóireála nua leictreachais-cheadaithe ag FDA
Tá Optune ceadaithe ag an FDA agus tá sé cumhdaithe ag go leor árachas.
Faoi láthair ceadaíonn an FDA teiripe allamuigh leictreach le haghaidh:
1. Treatment of adult patients with unresectable, locally advanced or metastatic mesothelioma (MPM), can be used with pemetrexed and platinum chemotherapy.
2. Adult patients (22 years or older) for histologically confirmed glioblastoma multiforme (GBM).
3. Temozolomide comhcheangailte chun cóireáil glioblastoma nua-dhiagnóisiú in othair aosacha.
4. Maidir le gliomas athfhillteach tar éis ceimiteiripe a fháil, is féidir glacadh le teiripe allamuigh leictreach leis féin.
The use of alternating low-intensity electric fields can destroy tumor cells and reduce damage to healthy tissues, which can effectively prevent side effects from affecting patients’ quality of life. Since 2000, the R & D team has been developing and expanding indications for electric field therapy. At present, researchers are conducting clinical trials on common solid tumors, including non-small cell lung cancer, non-small cell lung cancer brain metastasis, pancreatic cancer has launched phase III clinical trials, ailse ovarian and mesothelioma have completed phase II clinical trials, will soon Entered Phase III trials, and liver cancer is undergoing Phase II trials. These cancers have achieved very exciting clinical data.
Is scéim nua cóireála meall é an réimse leictreach cóireála meall Optune. Is cóireáil é seo a úsáideann minicíocht réimse leictreach ar leith chun cur isteach ar rannán cille, bac a chur ar fhás meall agus a chur faoi deara go bhfaighidh cealla ailse a mbíonn tionchar ag an réimse leictreach orthu bás. Dheimhnigh staidéir in vitro agus in vivo gur féidir le réimsí leictreacha cóireála meall fás meall a mhoilliú agus a aisiompú trí chosc a chur ar mhiotóis cealla meall.
Dúirt an saineolaí meall inchinne cáiliúil an Dr. Roger Stupp uair amháin:
“Fiche bliain ó shin, nuair a thosaigh mé ag cóireáil glioblastoma, fuair formhór na n-othar bás i níos lú ná bliain, agus ní raibh beagnach aon chásanna de mharthanas fadtéarmach. Ós rud é cóireáil réimse meall in éineacht le cóireáil temozolomide, gach 7 n-othar Mhair ceann acu níos mó ná 5 bliana. “
Ina theannta sin, tá dlúthbhaint ag éifeacht na cóireála allamuigh leictreach meall le comhlíonadh. Nuair a chaitheann othair níos mó ná 22 uair in aghaidh an lae, is féidir an ráta marthanais cúig bliana a mhéadú go 29.3%, atá beagnach 6 oiread an ráta marthanais foriomlán cúig bliana de theirmeozolómíd amháin! Níos tábhachtaí fós, níl beagnach aon fo-iarsmaí ag an modh cóireála seo de bharr chemoradiation. Is é an ceann is coitianta an gríos ar limistéar teagmhála an eochaircheap leictreoid. Tá sé seo gan fasach i stair na cóireála meall inchinn.
It is reported that Zaiding Pharmaceuticals is submitting an application for special approval of innovative medical devices to the State Drug Administration, and plans to submit an application for electric field therapy to be exempted from clinical trials. At the same time, it has completed a refinancing of US $ 200 million. Introduced Optune, a tumor electric field therapy, to start a new era of non-invasive tumor treatment! At present, you can go to Hong Kong through the Medical Department of Global Oncologist Network, and receive electric field treatment in Japan (400-666-7998)
I look forward to electric field therapy entering mainland China as soon as possible, and hope that this technology that brings huge survival benefits to cancer patients can enter medical insurance as soon as possible and bring the gospel to the majority of patients!
Tagairtí: https://www.pahomepage.com/news/using-electricity-to-treat-aggressive-brain-tumor/
